TY - JOUR
T1 - Heterogeneous clinical phenotypes of sporadic early-onset Alzheimer’s disease
T2 - a neuropsychological data-driven approach
AU - the LEADS Consortium
AU - Putcha, Deepti
AU - Katsumi, Yuta
AU - Touroutoglou, Alexandra
AU - Eloyan, Ani
AU - Taurone, Alexander
AU - Thangarajah, Maryanne
AU - Aisen, Paul
AU - Dage, Jeffrey L.
AU - Foroud, Tatiana
AU - Jack, Clifford R.
AU - Kramer, Joel H.
AU - Nudelman, Kelly N.H.
AU - Raman, Rema
AU - Vemuri, Prashanthi
AU - Atri, Alireza
AU - Day, Gregory S.
AU - Duara, Ranjan
AU - Graff-Radford, Neill R.
AU - Grant, Ian M.
AU - Honig, Lawrence S.
AU - Johnson, Erik C.B.
AU - Jones, David T.
AU - Masdeu, Joseph C.
AU - Mendez, Mario F.
AU - Musiek, Erik
AU - Onyike, Chiadi U.
AU - Riddle, Meghan
AU - Rogalski, Emily
AU - Salloway, Stephen
AU - Sha, Sharon
AU - Turner, R. Scott
AU - Wingo, Thomas S.
AU - Wolk, David A.
AU - Womack, Kyle
AU - Carrillo, Maria C.
AU - Rabinovici, Gil D.
AU - Dickerson, Bradford C.
AU - Apostolova, Liana G.
AU - Hammers, Dustin B.
AU - Grant, Ian
AU - Clark, David
AU - Toga, Arthur
AU - Polsinelli, Angelina
AU - Newell, Kathy
AU - Murray, Melissa E.
AU - Lagarde, Julien
AU - La Joie, Renaud
AU - Kukull, Walter A.
AU - Koeppe, Robert
AU - Kirby, Kala
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: The clinical presentations of early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease are distinct, with EOAD having a more aggressive disease course with greater heterogeneity. Recent publications from the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) described EOAD as predominantly amnestic, though this phenotypic description was based solely on clinical judgment. To better understand the phenotypic range of EOAD presentation, we applied a neuropsychological data-driven method to subtype the LEADS cohort. Methods: Neuropsychological test performance from 169 amyloid-positive EOAD participants were analyzed. Education-corrected normative comparisons were made using a sample of 98 cognitively normal participants. Comparing the relative levels of impairment between each cognitive domain, we applied a cut-off of 1 SD below all other domain scores to indicate a phenotype of “predominant” impairment in a given cognitive domain. Individuals were otherwise considered to have multidomain impairment. Whole-cortex general linear modeling of cortical atrophy was applied as an MRI-based validation of these distinct clinical phenotypes. Results: We identified 6 phenotypic subtypes of EOAD: Dysexecutive Predominant (22% of sample), Amnestic Predominant (11%), Language Predominant (11%), Visuospatial Predominant (15%), Mixed Amnestic/Dysexecutive Predominant (11%), and Multidomain (30%). These phenotypes did not differ by age, sex, or years of education. The APOE ɛ4 genotype was enriched in the Amnestic Predominant group, who were also rated as least impaired. Cortical thickness analysis validated these clinical phenotypes with dissociations in atrophy patterns observed between the Dysexecutive and Amnestic Predominant groups. In contrast to the heterogeneity observed from our neuropsychological data-driven approach, diagnostic classifications for this same sample based solely on clinical judgment indicated that 82% of individuals were amnestic-predominant, 9% were non-amnestic, 4% met criteria for Posterior Cortical Atrophy, and 5% met criteria for Primary Progressive Aphasia. Conclusion: A neuropsychological data-driven method to phenotype EOAD individuals uncovered a more detailed understanding of the presenting heterogeneity in this atypical AD sample compared to clinical judgment alone. Clinicians and patients may over-report memory dysfunction at the expense of non-memory symptoms. These findings have important implications for diagnostic accuracy and treatment considerations.
AB - Background: The clinical presentations of early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease are distinct, with EOAD having a more aggressive disease course with greater heterogeneity. Recent publications from the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) described EOAD as predominantly amnestic, though this phenotypic description was based solely on clinical judgment. To better understand the phenotypic range of EOAD presentation, we applied a neuropsychological data-driven method to subtype the LEADS cohort. Methods: Neuropsychological test performance from 169 amyloid-positive EOAD participants were analyzed. Education-corrected normative comparisons were made using a sample of 98 cognitively normal participants. Comparing the relative levels of impairment between each cognitive domain, we applied a cut-off of 1 SD below all other domain scores to indicate a phenotype of “predominant” impairment in a given cognitive domain. Individuals were otherwise considered to have multidomain impairment. Whole-cortex general linear modeling of cortical atrophy was applied as an MRI-based validation of these distinct clinical phenotypes. Results: We identified 6 phenotypic subtypes of EOAD: Dysexecutive Predominant (22% of sample), Amnestic Predominant (11%), Language Predominant (11%), Visuospatial Predominant (15%), Mixed Amnestic/Dysexecutive Predominant (11%), and Multidomain (30%). These phenotypes did not differ by age, sex, or years of education. The APOE ɛ4 genotype was enriched in the Amnestic Predominant group, who were also rated as least impaired. Cortical thickness analysis validated these clinical phenotypes with dissociations in atrophy patterns observed between the Dysexecutive and Amnestic Predominant groups. In contrast to the heterogeneity observed from our neuropsychological data-driven approach, diagnostic classifications for this same sample based solely on clinical judgment indicated that 82% of individuals were amnestic-predominant, 9% were non-amnestic, 4% met criteria for Posterior Cortical Atrophy, and 5% met criteria for Primary Progressive Aphasia. Conclusion: A neuropsychological data-driven method to phenotype EOAD individuals uncovered a more detailed understanding of the presenting heterogeneity in this atypical AD sample compared to clinical judgment alone. Clinicians and patients may over-report memory dysfunction at the expense of non-memory symptoms. These findings have important implications for diagnostic accuracy and treatment considerations.
KW - Alzheimer’s disease
KW - Clinical
KW - Cognition
KW - Early-onset
KW - Neuropsychology
KW - Phenotypes
KW - Variants
UR - http://www.scopus.com/inward/record.url?scp=85218291249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85218291249&partnerID=8YFLogxK
U2 - 10.1186/s13195-025-01689-8
DO - 10.1186/s13195-025-01689-8
M3 - Article
C2 - 39915859
AN - SCOPUS:85218291249
SN - 1758-9193
VL - 17
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
M1 - 38
ER -